On November 14, 2016 Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, reported that its lead drug candidate PB272 (neratinib) will be featured in 11 poster presentations at the 2016 San Antonio Breast Cancer Symposium (SABCS), December 6 – 10, 2016, in San Antonio, Texas (Press release, Puma Biotechnology, NOV 14, 2016, View Source [SID1234516643]). Abstracts are available to the public online on the SABCS website: www.sabcs.org.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster and poster discussion presentations are as follows:

OT1-02-05: Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults.
Wednesday, Dec. 7; 5:00 – 7:00 p.m. CST

P1-07-12: An exploratory correlative biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer.
Wednesday, Dec. 7; 5:00 – 7:00 p.m. CST

PD2-05: Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells.
Poster Discussion, Wednesday, Dec. 7; 5:00 – 7:00 p.m. CST

PD2-08: Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial.
Poster Discussion, Wednesday, Dec. 7; 5:00 – 7:00 p.m. CST

P2-03-05: Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (ERBB2) mutations in metastatic breast cancer patients.
Thursday, Dec. 8; 7:30 – 9:00 a.m. CST

P2-03-10: A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development.
Thursday, Dec. 8; 7:30 – 9:00 a.m. CST

P2-11-03: Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II CONTROL trial.
Thursday, Dec. 8; 7:30 – 9:00 a.m. CST

P3-03-03: An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer.
Thursday, Dec. 8; 5:00 – 7:00 p.m. CST

P3-05-02: Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization.
Thursday, Dec. 8; 5:00 – 7:00 p.m. CST

P4-12-06: Quantification of HER2-driven signaling (HER2 S ) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity.
Friday, Dec. 9; 7:30 – 9:00 a.m. CST

P4-21-10: Characterization of neratinib-induced diarrhea in patients with early-stage HER2+ breast cancer: Analyses from the phase III ExteNET trial.
Friday, Dec. 9; 7:30 – 9:00 a.m. CST